Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systematic review: microscopic colitis.

N Nyhlin1, J Bohr, S Eriksson

  • 1Department of Medicine, Division of Gastroenterology, Orebro University Hospital, Orebro, Sweden.

Alimentary Pharmacology & Therapeutics
|May 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Gender reassignment surgery from male to female].

Der Urologe. Ausg. A·2020
Same author

Publisher Correction: Interactions of the Calcite {10.4} Surface with Organic Compounds: Structure and Behaviour at Mineral - Organic Interfaces.

Scientific reports·2018
Same author

Sexuality after Male-to-Female Gender Affirmation Surgery.

BioMed research international·2018
Same author

Interactions of the Calcite {10.4} Surface with Organic Compounds: Structure and Behaviour at Mineral - Organic Interfaces.

Scientific reports·2017
Same author

Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease - authors' reply.

Alimentary pharmacology & therapeutics·2016
Same author

The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2016
Same journal

Letter on: Pre-Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial.

Alimentary pharmacology & therapeutics·2026
Same journal

Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.

Alimentary pharmacology & therapeutics·2026
Same journal

Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.

Alimentary pharmacology & therapeutics·2026
Same journal

Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study.

Alimentary pharmacology & therapeutics·2026
Same journal

A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection.

Alimentary pharmacology & therapeutics·2026
Same journal

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.

Alimentary pharmacology & therapeutics·2026
See all related articles

Microscopic colitis, including collagenous and lymphocytic types, causes chronic diarrhea. Budesonide shows promise for collagenous colitis short-term treatment, but more research is needed for long-term strategies and lymphocytic colitis therapies.

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Pathology

Background:

  • Microscopic colitis, encompassing collagenous colitis and lymphocytic colitis, is a frequent cause of chronic non-bloody diarrhea, particularly in elderly women.
  • The etiology of microscopic colitis remains unknown, though an association with autoimmune diseases is observed.

Purpose of the Study:

  • To conduct a systematic review of microscopic colitis.
  • To synthesize current knowledge on the clinical and epidemiological aspects of microscopic colitis.

Main Methods:

  • A comprehensive literature search was performed using PubMed.
  • Keywords included "microscopic colitis," "collagenous colitis," "lymphocytic colitis," and "chronic diarrhea."

Main Results:

Related Experiment Videos

  • The annual incidence for both collagenous and lymphocytic colitis is 4-6 per 100,000 inhabitants.
  • Budesonide is the most supported short-term treatment for collagenous colitis, with a pooled odds ratio for clinical response of 12.3 (95% CI: 5.5-27.5) compared to placebo.
  • Evidence for other treatments is limited, and controlled trials for lymphocytic colitis are lacking. Long-term prognosis is generally good with rare complications and no increased mortality.

Conclusions:

  • Clinical and epidemiological features of microscopic colitis are well-established.
  • Budesonide is effective for short-term collagenous colitis management, but optimal long-term treatment requires further investigation.
  • Controlled treatment data for lymphocytic colitis is anticipated.